



SSIT is Revolutionizing Rehabilitation with AI & Immersive Tech Empowering Recovery Through Innovation Globally

\$1M Pre-Seed Round Investment Opportunity

Safe Harbor Statement

This presentation includes forward-looking statements and projections regarding the potential investment returns of SSIT. These statements are for informational purposes only and are not guarantees of future performance. While comparisons to other companies, such as Penumbra, are used as illustrative examples, they should not be interpreted as an average or expected return on investment for SSIT. The performance of any investment in SSIT will depend on numerous factors, including market conditions, company growth, regulatory milestones, and other unpredictable variables. Prospective investors are encouraged to conduct their own due diligence and seek independent financial advice before making any investment decisions.

Dr Vik Ahluwalia, Founder CEO

Rehabilitation Needs Modern, Data-Driven Solutions

< 2024 SSIT Pitch Deck. >

- 1 50M people of all ages annually undergo rehab therapy in the US alone yearly;
- 2 But traditional rehab is slow, expensive, and lacks personalization;
- 3 Limited access to quality care and tracking, limits outcomes.



It's a Problem for Therapists and Patients Globally, causing:

- 1 Low Patient Engagement and Motivation;
- 2 Inconsistent Home Exercise Adherence;
- 3 Time Constraints for Therapists;
- 4 Lack of Real-Time Feedback;
- 5 Varying Patient Progress;
- 6 Data Tracking and Monitoring issues;
- 7 Physical and Cognitive Barriers

For a Lot of Therapists and their Patients

440,000
Licensed
Therapists
USA

• Simple Text

38,800
Licensed
Therapy
Centers,
Clinics &
Hospitals

LICENSED PHYSICAL AND
OCCUPATIONAL THERAPISTS

LICENSED PHYSICAL AND
OCCUPATIONAL THERAPISTS

Treating
100-200
Patients per
Day on average

• Simple Text

LICENSED PHYSICAL AND
OCCUPATIONAL THERAPISTS

Providing
Physical,
Occupational,
Neurological
Therapy

LICENSED PHYSICAL AND
OCCUPATIONAL THERAPISTS

Tapping into a \$100B Global Market

\$100BN

ANNUAL
GLOBAL
MARKET

**\$46BN
TAM**

ANNUAL USA
MARKET

**\$30BN
SAM**

OUR
POTENTIAL
TARGETS

**\$2BN YOY
SOM**

OUR POTENTIAL
ANNUAL REVENUE
WITH JUST 5%
TARGET CAPTURE

TOTAL ADDRESSABLE
MARKET IN USA

SERVICEABLE AVAILABLE
MARKET IN USA

OUR OBTAINABLE
MARKET IN USA

Our Solution

AI-Powered VR Therapy: Engaging, Personalized, Effective

- 1 AI-driven therapy that adapts in real-time to patient progress;
- 2 Engaging, gamified VR exercises that increase compliance;
- 3 Remote access through VR allows home-based therapy continuity.

AI Tailored Therapy

Real-Time Progress, Real-Time Tracking, Real-Time Results

How It Works: Personalized Rehabilitation in Action

Step 1: Patient puts on the VR headset;

Step 2: Exercises guided by the SSIT AI engine;

Step 3: Therapist reviews real-time data;

Step 4: Patients monitors via the AI App;

Step 5: AI Platform identifies patient progress and ongoing rehab options for therapist.




SSIT AI APP

Managing A Seamless Blend of AI, VR, and Gamified Rehabilitation

Step 1: The App captures and records patient treatments;
Step 2: It matches treatment against expected progress;
Step 3: The App measures the progress and correlates data;
Step 4: The Therapist can monitor and identify treatment
changes and progress is managed.

How SSIT Works: Real-Time Tracking



Case Study: Proven Impact and Results

Real-World Results: Transforming Patient Outcomes

Real-world application in outpatient rehab centers (example case: 6-week program outcome)




- ❖ Early trials show increased patient engagement by 40%;
- ❖ Clinically tested: 30% faster recovery times than traditional rehab methods;
- ❖ More Beta Testing and IRB trials being prepared.



Study Published Oct 18, 2024

<https://biomedgrid.com/pdf/AJBSR.MS.ID.003201.pdf>



Outstanding performance significantly beating traditional and conventional therapy across six major treatment protocols.

IRB Trials approved in neuro-rehabilitation tests for 2025.

CONCLUSION:

This review shows the promise of efficacy of the Virtual Reality (VR) rehabilitation and suggests that it is suitable, effective, superior or at least complementary to the traditional Physical Therapy and Rehabilitation process may be a potential tool for neuro-therapy, neuro-rehabilitation, and fall prevention in children, young adults and geriatrics population.


VR Therapy is a treatment that can help people confront and process traumatic experiences in a safe and controlled environment, including Neurological & Physical Conditions | PTSD | Phobias | Autism

< 2024 SSIT Pitch Deck. >

Competitive Advantage: Leading the Way in Tech-Driven Rehabilitation

Outpacing Competitors with AI-Powered Customization

- 1 Competitors like Penumbra and ReWalk focus on hardware-based solutions;
- 2 SSIT is unique: AI-driven personalization, VR gamification, no external sensors needed;
- 3 Scalability: Works in clinics or at home, offering broad applications.




- 2024 USPTO PATENT PENDING
- 2024 USPTO TRADEMARK
- SECRET SAUCE ALGORITHMS

#1 Competitor Overview: Penumbra

- ❖ Penumbra raised \$2.9M in 2012;
- ❖ IPO in 2015 at \$40 and rose to current \$233 with high of \$344.06 in 2023;
- ❖ Penumbra Market Cap \$8.97BN and has 38M shares;
- ❖ Sold 4M shares at IPO raising \$129M at \$30 share;
- ❖ ***\$25K (0.86%)** invested in 2012 at the very start would now be valued at over **\$60M** now (240,000%)

*Please view our Financial Disclaimers and Safe Harbor Provisions

\$25K
2012




\$60M
2024

#2 Competitor Overview: XR Health

- ❖ Israel backed Startup Health raised \$4M in 2018 then \$7M in 2020;
- ❖ Uses VR and Telemedicine – focusing on At-Home virtual therapy and does not have AI;
- ❖ \$40M in funding to date with a market cap of around \$120M;
- ❖ Still a private company;

*Please view our Financial Disclaimers and Safe Harbor Provisions

\$25K
2018



\$750K
2024

Business Model: Revenue Streams and Growth Plan

High-Margin, Scalable Revenue Model

- 1 Leveraged trusted sale via industry vendor working on commission sales and reselling;
- 2 Hardware: \$7,600 per dual system sold (discounted for early adopters);
- 3 SaaS subscription: *\$199/month per therapist for AI platform and support;
- 4 Expansion into consumer-facing home therapy in future phases.

*Conservative SaaS Monthly Subscription – will be increased to market acceptance

Go-to-Market Strategy: Targeting Clinics and Therapists

Strategic Partnerships and Rapid Market Penetration

- 1 Focus on partnerships with clinics, rehabilitation centers, and therapists identifying Insurance Code CPT 0770T;
- 2 Pre-sales to 500 therapists generating ~\$3.5M – avoiding second equity round and share dilution with free SSIT Certification;
- 3 B2B model initially, moving to B2C in future phases;
- 4 Targeting rollout up to 39-49,000 therapists by end of year 5;

Benefits for Therapists

1

Additional Revenue Stream: Charge premium rates for advanced VR sessions. **Reduced Dropout Rates:** VR therapy keeps patients engaged, improving retention. **Insurance Code CPT code 0770T** for AI/VR therapy protocols.

2

Improved Patient Outcomes: Engaging VR therapy supports faster, more effective recovery.

3

Competitive Advantage: Attract new patients by offering cutting-edge VR-based rehab.

4

Higher Treatment Capacity: Serve more clients by streamlining session workflows.

5

Continuous Upgrades: Subscription covers support, updates, and new therapy modules.

Break-Even
3-4 Months

Annual ROI
284%

Min Av \$21K
Annual
Additional
Income/Unit

Extra \$40K+
Home/Clinic
Neuro Client
Revenue/Unit

5 Yr Financials P&L

Revenue
\$272M
By Year 5

Clients
49,000
By Year 5

Market Cap
+\$1BN
By Year 5

Profit and Loss at a Glance										
	2026		2027		2028		2029		2030	
Revenue	\$ 6,016,429	100%	\$ 20,148,727	100%	\$ 50,570,387	100%	\$ 118,516,376	100%	\$ 272,934,580	100%
Cost of Goods Sold	\$ 163,751	3%	\$ 167,600	1%	\$ 175,385	0%	\$ 191,856	0%	\$ 227,424	0%
Gross Profit	\$ 5,852,677	97%	\$ 19,981,127	99%	\$ 50,395,002	100%	\$ 118,324,519	100%	\$ 272,707,156	100%
Operating Expenses	\$ 2,014,917	33%	\$ 7,628,356	36%	\$ 17,154,418	34%	\$ 37,768,075	32%	\$ 86,227,051	32%
Net Income	\$ 3,837,760	48%	\$ 9,257,078	46%	\$ 24,930,438	49%	\$ 60,462,333	51%	\$ 139,860,079	51%
EBITDA	\$ 3,879,261	64%	\$ 12,384,271	61%	\$ 33,282,084	66%	\$ 80,657,944	68%	\$ 186,521,605	68%

EBITDA is earnings before interest, tax, depreciation, and amortization.

Summary Data					
	2026	2027	2028	2029	2030
New Customers	2,862	4,192	8,855	18,968	41,315
Average Customers	1,327	4,242	10,140	22,618	49,563
Total Marketing Spend	\$ 132,000	\$ 1,461,814	\$ 3,215,439	\$ 7,039,087	\$ 16,103,436
Customer Acquisition Cost	\$ 46	\$ 349	\$ 363	\$ 371	\$ 390
Avg Monthly Revenue per Customer	\$ 377	\$ 395	\$ 415	\$ 436	\$ 459
Year End MRR	\$ 908,692	\$ 2,517,106	\$ 6,073,785	\$ 14,071,177	\$ 32,379,160
ARR (based on Year End MRR)	\$ 10,904,304	\$ 30,205,268	\$ 72,885,424	\$ 168,854,129	\$ 388,549,923
Annual Churn Rate	8%	8%	8%	8%	8%
Avg Customer Relationship Length (Years)	13	13	13	13	13
Customer Lifetime Value	\$ 56,578	\$ 59,278	\$ 62,280	\$ 65,457	\$ 68,804
Employees	6	62	133	293	659
Revenue per Employee	\$ 1,002,738	\$ 324,979	\$ 380,228	\$ 404,493	\$ 414,165

Revenue on fewer than 12.5% of the Therapist market over 5 years

5-YR Income Statement

TOTAL SALES
\$272M
By Year 5

OPERATING EXPENSES
\$86M

EBITDA
\$186M
By Year 5

SSIT Income Statement					
For the Year Ended May 31,	2026	2027	2028	2029	2030
Sales					
Subscription Revenue	6,005,429	20,118,623	50,523,898	118,442,365	272,814,341
Other Revenue	11,000	30,105	46,489	74,010	120,239
Total Sales	\$ 6,016,429	\$ 20,148,727	\$50,570,387	\$ 118,516,376	\$ 272,934,580
Cost of Goods Sold					
Direct Expenses	163,751	167,600	175,385	191,856	227,424
Total Cost of Goods Sold	\$ 163,751	\$ 167,600	\$ 175,385	\$ 191,856	\$ 227,424
Gross Margin					
Percent	97%	99%	100%	100%	100%
Operating Expenses					
Sales and Marketing	132,000	77,466	88,302	100,833	115,328
General and Administrative	340,000	2,533,800	6,132,002	13,746,506	31,514,247
Development & Maintenance	95,500	49,440	50,923	52,451	54,024
Sales and Marketing Salaries	-	1,384,348	3,127,137	6,938,254	15,988,109
General and Administrative Salaries	387,625	402,331	476,598	495,753	515,865
Development & Maintenance Salaries	523,292	2,654,471	6,742,956	15,837,779	37,502,978
0	-	-	-	-	-
Depreciation and Amortization	41,500	41,500	41,500	41,500	41,500
Total Operating Expenses	\$ 2,014,917	\$ 7,638,356	\$17,154,418	\$ 37,708,075	\$ 86,227,051
Pre-Tax Income	\$ 3,837,761	\$ 12,342,771	\$33,240,584	\$ 80,616,444	\$ 186,480,105
Income Tax	959,440	3,085,693	8,310,146	20,154,111	46,620,026
Net Income	\$ 2,878,321	\$ 9,257,078	\$24,930,438	\$ 60,462,333	\$ 139,860,079
EBITDA	\$ 3,879,261	\$ 12,384,271	\$33,282,084	\$ 80,657,944	\$ 186,521,605


(Earnings Before Interest, Taxes, Depreciation, and Amortization)

Revenue on fewer than 12.5% of the Therapist market over 5 years

Funding Ask: Investment Opportunity

\$1M to Launch, Scale, and Transform Rehabilitation Reg D Rule 506(b) SEC

< 2024 SSIT Pitch Deck. >



- ❖ Seeking \$1M in a Friends, Family & Colleagues Angel round;
- ❖ Convertible Note 7.5% + 25 % discount at equity over 18 months;
- ❖ IRS Code 12 44 Stock first \$1M raised
- ❖ Use of funds: IRB testing, beta testing expansion, marketing collateral, fractional staffing - 12 months Runway;

Exit Strategy: Long-Term Vision

IPO or M&A – A \$2B Market Cap in Sight < 5 Yrs

- 1 Path to IPO after achieving >\$200M+ in revenue by year 5 and \$1BN market cap;
- 2 Potential for M&A with strategic partners like Penumbra or ReWalk;
- 3 Investors can expect high exit potential through strategic sale or public offering;
- 4 *ROI expected 35-50 times investment

*Please view our Financial Disclaimers and Safe Harbor Provisions

SSIT TEAM Can Execute

Dr. VIK ALHUWALIA, PT, DPT. CEO, Co-Founder



Dr. Vik holds a Doctor of Physical Therapy degree from Massachusetts General Hospital IHP, a Harvard affiliate, and an MBA from the University of Alabama in Business Finance. Since 1993, he has owned and operated Professional Physical Therapy and Rehab Centers across Michigan. With over 30 years of experience, Dr. Vik specializes in Physical Therapy and Rehabilitation, focusing on auto accidents, work-related, and personal injuries. His expertise extends to balance, vertigo, BPPV, and neurological conditions, setting him apart with his comprehensive patient analysis and injury case insights.

DR. SMITA AHLUWALIA, PT, DPT. Co-founder



Dr. Smita, a Doctor of Physical Therapy from Massachusetts General Hospital IHP, an academic affiliate of Harvard University, leads clinical operations as Chief Clinician. She ensures quality assurance in patient care, documentation, facility upkeep, employee training, and policy development to optimize rehabilitative services for the community. Specializing in Orthopedics, Sports Medicine, and Women's Health Rehabilitation, Dr. Smita has developed numerous protocols for Balance, Vertigo, BPPV, and other neurological conditions.

BRAD DUFFY, COO



Serial Entrepreneur – Medical Devices and products including Skins Compression wear for a range of sports and health treatments \$200M Startup. Science graduate and MBA. C-Level Manager and CFO. Experienced FDA and SEC compliance manager.

SSIT TEAM Advisory Board



DR. NARAYAN VERMA, MD, FACP, FAAN, FAASM

A SSIT Board Member and Medical Director, recognized as a "Top Doc" in HOUR Detroit and US News & World Report from 2004 to 2024, with over 300 five-star reviews in US News. He is a Professor of Neurology at Oakland University William Beaumont School of Medicine. Dr. Verma has authored numerous publications and pioneered the use of innovative biomedical technologies, including Neuro-Trax for neuro-psychological testing, balance testing for ambulation issues, and autonomic testing for fainting and neuropathies.



JOSEPH P. MICHAEL

Board Member and Advisor, brings over five decades of experience, including service in the U.S. Army during the Korean War and senior leadership roles in banking. As Senior Vice President at Federal Savings Bank & Trust, he facilitated loans up to \$25 million. Currently, he serves as a board member and financial advisor to Raustyn Holdings, providing strategic financial guidance. Joseph is also dedicated to philanthropy, supporting organizations like St. Jude and raising human trafficking awareness through the Knights of Columbus at St. John Vianney.



DR. MARK DUKAJ, MD

SSIT Board Member, is a specialist in Internal Medicine with hospital privileges at Ascension St. John Hospital Systems. With decades of experience in both in-patient and out-patient care, Dr. Dukaj has deep expertise in diagnosing and managing a wide range of medical conditions. He has taught physician assistant students from the University of Detroit and served as head of the Internal Medicine Department at St. Clair Specialty Physicians for nearly a decade. Dr. Dukaj is also the Associate Director of the Post Polio Clinic and a member of the Quality Care Committee at St. John Macomb Hospital.



DR. SAM JAMES, PH.D., MBA, OTR/L

is EVP of Technology and Strategy and an Advisory Board Member. With a Ph.D. in Systems Engineering and an Executive MBA, he combines technical and business expertise. As COO of Rafa Therapies, Inc., he oversees clinic operations and serves as an Assistant Professor at Eastern Michigan University. Dr. James has published nine scientific articles, contributed to telerehabilitation systems and medical device biomechanics, and led rehabilitation programs at Select Specialty Hospital. He is recognized for his patient care innovations, teaching, and leadership. Outside of work, Dr. James is passionate about organic gardening and sustainability.

Let's Change the Future of Recovery Together

Invest as an Early-Stage Investor in SSIT today

Contact Dr. Vik Ahluwalia:

Min Investment \$25K + \$5K increments

Max Investment \$250K

Accredited Investors

Investment opens November 15, 2024 – 3 Months.

www.ssitrehab.com

Thank you

Empowering Every Healthcare Provider and Patient
with Personalized, Data-Driven Rehabilitation for
Faster, Smarter, and Measurable Recovery

< 2024 SSIT Pitch Deck. >